Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY.

SynBiotic SE: Resolution to carry out a capital increase

Munich, September 2, 2022 - The Board of Directors of SynBiotic SE today resolved to exercise part of the existing authorized capital to increase the Company's share capital in the amount of EUR 4.184.900 by up to EUR 334,000 to up to EUR 4.518,900 by issuing up to 334,000 new no-par value bearer shares against cash contributions (the „New Shares“). The New Shares will be issued at an issue price of EUR 1.00 per share and at a placement price of EUR 15.00 per share. The New Shares shall carry full dividend rights from January 1, 2021. Shareholders' subscription rights are excluded. The New Shares have been offered to the Small and Mid Cap Investmentbank AG, Munich, for subscription with the obligation to offer the New Shares for purchase to institutional investors in a private placement at the placement price of EUR 15.00 per share. The New Shares are to be offered to interested investors in the course of a 2-week roadshow now following. One of the main shareholders, Apeiron Investment Group, has today agreed with the Company to subscribe for the New Shares in the amount of up to EUR 1 million.

The proceeds from the placement will be used to further expand the operating business of Europe's largest group of companies in the hemp and cannabissector, especially in light of the ongoing legalization process of cannabis for recreational use. As part of the buy & build investment approach, suitable acquisition candidates will continue to be analyzed, for which the proceeds may also be used.

About SynBiotic SE:

SynBiotic SE is a platform company with an EU-focused buy & build investment approach. The focus is on the alternative production of functionally superior cannabinoids as well as the development of wellness & pharmaceutical product formulations for the end customer under own brands. In addition, the company stands for the synthetic production of cannabinoids, the development of medicinal and

nutritional supplements as well as cosmetic products.

‍